- Global Pharma News & Resources

Peanut Allergy Competitive Landscape Report 2018 - Market Insights, Epidemiology and Market Forecast to 2025 -

The "Peanut Allergy - Competitive Landscape, Market Insights, Epidemiology and Market Forecast 2025" drug pipelines has been added to's offering.

Peanut Allergy - Competitive Landscape, Market Insights, Epidemiology and Market Forecast 2025 provides comprehensive insights on the therapeutics development and the global market trends for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The report covers the therapeutics market revenue, treatment practice and Peanut Allergy forecasted market share from 2017 to 2025, along with the global epidemiological forecast for this indication.

The reported prevalent cases of Peanut Allergy in 2015 were 6,719,025 in 7MM and estimated to increase in coming years. In certain European countries prevalence will decrease owing to the overall decrease in population. Currently there is no effective therapeutics or prophylactic products are available in market. The historical and current market size for this allergy comprises of Epinephrine and Anti-histamines. The first entry of Peanut Allergy treatment is expected in 2019 in US.

The report also includes therapeutic competitive landscape including 15+ pipeline products in this space. It further provides comparative pipeline analysis at various stages covering Phase III, Phase II, Phase I, Pre-clinical and Discovery. Active pipeline therapeutics assessment by stage, therapy type, route of administration and molecule type is also provided. Additionally, it also features the dormant and discontinued pipeline products. Leading companies in this space are Aimmune, DBV Technologies and AnaptysBio.

Key Topics Covered:

  1. Peanut Allergy - Overview
  2. Peanut Allergens
  3. Symptoms
  4. Clinical Symptoms
  5. Risk Factors
  6. Causes
  7. Test and Diagnosis
  8. Peanut Allergy Management and Treatment
  9. Being prepared for a reaction
  10. Prevalence
  11. Scientific Research
  12. Experimental Approaches
  13. Sensitization
  14. To Do/Not to Do
  15. Epidemiology Overview - 7MM, 2015-2025
  16. Comparative Analysis
  17. Product Type
  18. Late Stage Products (Phase III)
  19. AR101: Aimmune Therapeutics
  20. ANB020: AnaptysBio
  21. SAR-439794: Sanofi
  22. SVP-CPE + SVP-Resiquimod: Selecta Biosciences
  23. Assessment by Route of Administration
  24. Assessment by Stage and Route of Administration
  25. Assessment by Molecule Type
  26. Assessment by Stage and Molecule Type
  27. Dormant and Discontinued Products
  28. Comparative Analysis
  29. Market Assessment: 7MM
  30. Appendix

Companies Mentioned

  • Aimmune
  • Allergy Therapeutics
  • AnaptysBio
  • ASIT biotech
  • BioLingus
  • DBV Technologies
  • Genentech
  • Laboratorios LETI
  • Prota Therapeutics
  • Selecta Biosciences
  • Virtici

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 03-Dec-2018